CMS Francis Lefebvre Advises Transgene on Capital Increases Totaling €144.3 Million

CMS Francis Lefebvre advised Transgene, CMS UK advised on US securities law aspects for Transgene, and Goodwin advised the bank syndicate comprising Van Lanschot Kempen N.V. and Swiss Life Banque Privée. Transgene, a biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer whose shares are admitted to trading on Euronext Paris, has completed capital raises totalling €144.3 million. It successfully raised €105 million through the issuance of new shares to French and European investors specialising in the health sector via a private placement implemented through an accelerated bookbuilding and to retail investors via a public offering in France and in certain other EU countries through the PrimaryBid platform. Concurrently, Transgene carried out a capital increase reserved for TSGH (Institut Mérieux) of €39.3 million by way of set-off with amounts advanced under a current account advance granted by TSGH to Transgene. Transgene intends to use the net proceeds primarily to accelerate its myvac® programme, including funding the ongoing Phase 2 trial in head and neck cancer, launching a Phase 1 trial in a new indication, optimising manufacturing, and undertaking initial work to prepare for a pivotal trial in head and neck cancer. CMS Francis Lefebvre represented Transgene with a team composed by: Bertrand Sénéchal, partner; Victor Delion, associate; Natan Bisson-Kocanski, lawyer. CMS UK represented Transgene with a team composed by: David Rivera, counsel (advising on US securities law aspects). Goodwin represented the bank syndicate composed of Van Lanschot Kempen N.V. and Swiss Life Banque Privée.

CMS Francis Lefebvre Advises Transgene on Capital Increases Totaling €144.3 Million

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads